OPEN END TURBO BEAR OPTIONSSCHEIN - ASTRAZENECA | Real-time BOERSE MUENCHEN 01:15:37 27/06/2024 pm IST | ||
| 1.51 EUR | +1.34% |
|
| Current month | -18.58% | ||
| 1 month | -12.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 1.51 | +1.34% |
| 26/24/26 | 1.49 | +0.68% |
| 25/24/25 | 1.48 | -5.13% |
| 24/24/24 | 1.56 | +1.30% |
| 21/24/21 | 1.54 | -6.67% |
Real-time BOERSE MUENCHEN
Last update June 27, 2024 at 01:15 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HC3BN3 |
| ISIN | DE000HC3BN39 |
| Date issued | 20/01/2023 |
| Strike | 13,763 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.92 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.14 € |
|---|---|
| Lowest since issue | 1.34 € |
| Spread | 0.01 € |
| Spread % | 0.66% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
158.5
USD
Average target price
174.4
USD
Spread / Average Target
+10.04%
- Stock Market
- Certificates
- Certificat
